Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07539415 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Apr 30, 2026 → Oct 27, 2026
See other at-risk trials from Daewoong Pharmaceutical Co. LTD.

Record History

  1. Primary completion pushed from Apr 30, 2026 to Oct 27, 2026 Recruitment opened · Completion pushed from Aug 30, 2026 to Nov 17, 2026 · Start date changed from estimate of Mar 30, 2026 to May 6, 2026 · 1 morev2 Show 4 more changesShow less
    • Recruitment opened
    • Completion pushed from Aug 30, 2026 to Nov 17, 2026
    • Start date changed from estimate of Mar 30, 2026 to May 6, 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Daewoong Pharmaceutical Co. LTD.
34 trials monitored
See 1 trial at risk
Diabetes
4,286 trials monitored
See 187 trials at risk
Obesity
3,560 trials monitored
See 142 trials at risk
Type 2 Diabetes
2,100 trials monitored
See 102 trials at risk
Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults
Trial Details
NCT Number NCT07539415
Lead Sponsor Daewoong Pharmaceutical Co. LTD.
Conditions Obesity & Overweight, Type 2 Diabetes
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov